Tech writer Synchrogenix acquired by private equity firm

0
Ellen Barrose
Ellen Barrose

North Wilmington-based health care technical writing service Synchrogenix has been acquired by a private equity firm that will merge the Delaware company into a consulting practice.

Terms were not disclosed.

New York-based Arsenal Capital Partners, which invests in middle market healthcare, specialty industrial, and financial services companies, announced that Synchrogenix will be merged into Certara, a drug development and drug safety consultancy acquired by Arsenal in December. 

Stephen McLean, a partner at Arsenal and co-head of the firm’s Healthcare Group, said, “Pharmaceutical companies are looking for greater value and increased synergies from their outsourcing partners. Adding the complementary services Synchrogenix offers to the Certara portfolio will allow Certara to provide its preclinical and clinical pharmacology customers with end-to-end drug development consulting and writing services.

Donald Deieso, an operating partner at Arsenal and co-head of the healthcare Group, said, “We were attracted to Synchrogenix by the quality of its work, its outstanding reputation and the global network of regulatory experts that it has developed. By combining the most sophisticated regulatory professional organization with the world’s leading computational drug development capabilities, we believe that Certara can continue to enable our clients to improve the pace of efficacious drug development for the benefit of patients around the world.”

Certara provides its global pharmaceutical and biotechnology customers with scientific informatics and analytics, including molecular modeling, population-based simulations, pharmacokinetic analyses and clinical trial simulations. Certara has more than 225 employees located at offices in the US, UK, Canada, and Japan. 

Synchrogenix is the largest independent regulatory-writing practice in the world. It has more than 50 permanent regulatory writers and editors on staff in seven offices in North America, Europe, and Asia. The company provides pre-clinical, clinical, CMC and drug safety writing, and global regulatory submission services.

“Having worked with our talented staff to build Synchrogenix from the ground up, I was looking for a like-minded company that shared our strong work ethic and focus on excellent customer service and high-quality results. We have found a great match in Arsenal and Certara, and I look forward to expanding the range of services that we offer to all of our customers,” said Synchrogenix CEO Ellen Barrosse.  Barrosse will remain the CEO of Synchrogenix following the transaction.

Barrose founded the company in 1986. In recent years, she has been active in political circles after being elected Republican National Committewoman for Delaware. Prior to that time, she was prominent in the right to life movement in the state.

Facebook Comments